Cargando…

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system

AIM: The aim of this study was to identify potential safety concerns associated with Sacituzumab Govitecan (SG), an antibody-drug conjugate targeting trophoblastic cell-surface antigen-2, by analyzing real-world safety data from the largest publicly available worldwide pharmacovigilance database. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gui, Xiujuan, Zhao, Jianli, Ding, Linxiaoxiao, Chai, Jie, Lai, Hongna, Cai, Yangyang, Luo, Simin, Zeng, Yinduo, Wu, Wenjing, Chen, Haizhu, Yao, Herui, Wang, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587566/ https://www.ncbi.nlm.nih.gov/pubmed/37869095 http://dx.doi.org/10.3389/fonc.2023.1276976

Ejemplares similares

Sacituzumab Govitecan: First Approval
por: Syed, Yahiya Y.
Publicado: (2020)

Sacituzumab govitecan for breast cancer
Publicado: (2022)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan
por: Prescott, Adam Ethan, et al.
Publicado: (2022)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
por: Lang, Yitian, et al.
Publicado: (2023)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
por: Vranic, Semir
Publicado: (2023)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
por: Michaleas, S., et al.
Publicado: (2022)

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
por: Cheng, Shao-Xian, et al.
Publicado: (2023)

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
por: Cardillo, Thomas M., et al.
Publicado: (2020)

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer
por: Webster, Emily M., et al.
Publicado: (2020)

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
por: Chen, Jigang, et al.
Publicado: (2021)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
por: Pavone, Giuliana, et al.
Publicado: (2021)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
por: Fontes, Mariane S, et al.
Publicado: (2022)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
por: di Mauro, Pierluigi, et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
por: Lambertini, M., et al.
Publicado: (2020)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
por: Xie, Jiao, et al.
Publicado: (2023)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
por: Santi, Daniel V., et al.
Publicado: (2021)

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
por: Carey, Lisa A., et al.
Publicado: (2022)

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2015)

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes
por: Yap, Timothy A., et al.
Publicado: (2022)

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Avila, Jorge, et al.
Publicado: (2023)

Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer
por: Matusz-Fisher, Ashley, et al.
Publicado: (2022)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020)

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2020)

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm
por: Olivier, Timothee, et al.
Publicado: (2021)

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
por: Coates, James T., et al.
Publicado: (2021)

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus
por: Hoppe, Sascha, et al.
Publicado: (2022)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4vvvndk12iu5qm7ibk934iu008